XML 32 R13.htm IDEA: XBRL DOCUMENT
v3.25.1

TAXES BASED ON INCOME | 12 Months Ended
--- | ---
Feb. 01, 2025
TAXES BASED ON INCOME |
TAXES BASED ON INCOME |
4. | TAXES BASED ON INCOME
​ The provision for taxes based on income consists of: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2024 |  | 2023 |  | 2022 |
Federal | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current | ​ | $ | 622 | ​ | $ | 707 | ​ | $ | 401 | ​
Deferred | ​ |  | (62) | ​ |  | (130) | ​ |  | 162 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Subtotal federal | ​ |  | 560 | ​ |  | 577 | ​ |  | 563 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
State and local | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current | ​ |  | 97 | ​ |  | 114 | ​ |  | 91 | ​
Deferred | ​ |  | 13 | ​ |  | (24) | ​ |  | (1) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Subtotal state and local | ​ |  | 110 | ​ |  | 90 | ​ |  | 90 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total | ​ | $ | 670 | ​ | $ | 667 | ​ | $ | 653 | ​
​ A reconciliation of the statutory federal rate and the effective rate follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2024 |  | 2023 |  | 2022 |
Statutory rate |  | 21.0 | % | 21.0 | % | 21.0 | %
State income taxes, net of federal tax benefit |  | 2.6 | ​ | 2.5 | ​ | 2.5 | ​
Credits |  | (0.8) | ​ | (1.1) | ​ | (0.8) | ​
Resolution of tax audit examinations |  | (0.2) | ​ | — | ​ | (0.2) | ​
Excess tax benefits from share-based payments | ​ | (0.9) | ​ | (0.7) | ​ | (1.9) | ​
Impairment of goodwill related to Vitacost.com | ​ | — | ​ | — | ​ | 1.2 | ​
Non-deductible legal settlements | ​ | (0.1) | ​ | 1.4 | ​ | — | ​
Non-deductible executive compensation | ​ | 0.2 | ​ | 0.3 | ​ | 0.5 | ​
Tax benefit from sale of Kroger Specialty Pharmacy | ​ | (0.9) | ​ | — | ​ | — | ​
Other changes, net |  | (0.9) | ​ | 0.1 | ​ | 0.2 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Effective income tax rate |  | 20.0 | % | 23.5 | % | 22.5 | %
​ The 2024 tax rate differed from the federal statutory rate due to a tax benefit from recognizing deferred tax assets related to the sale of Kroger Specialty Pharmacy, the benefit from share-based payments and the utilization of tax credits, partially offset by the effect of state income taxes. ​ The 2023 tax rate differed from the federal statutory rate due to the effect of state income taxes and the nondeductible portion of opioid settlement charges, partially offset by the benefit from share-based payments and the utilization of tax credits. ​ The 2022 tax rate differed from the federal statutory rate due to the effect of state income taxes and non-deductible goodwill impairment charges related to Vitacost.com, partially offset by the benefits from share-based payments and the utilization of tax credits. ​ The tax effects of significant temporary differences that comprise tax balances were as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2024 |  | 2023 |
Deferred tax assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Compensation related costs | ​ | $ | 338 | ​ | $ | 361 | ​
Lease liabilities | ​ |  | 2,126 | ​ |  | 2,100 | ​
Closed store reserves | ​ |  | 58 | ​ |  | 51 | ​
Net operating loss and credit carryforwards | ​ |  | 70 | ​ |  | 76 | ​
Deferred income | ​ | ​ | 83 | ​ | ​ | 102 | ​
Legal settlements | ​ | ​ | 303 | ​ | ​ | 313 | ​
Allowance for uncollectible receivables | ​ | ​ | 24 | ​ | ​ | 30 | ​
Other | ​ | ​ | 44 | ​ |  | — | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Subtotal | ​ |  | 3,046 | ​ |  | 3,033 | ​
Valuation allowance | ​ |  | (54) | ​ |  | (55) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total deferred tax assets | ​ |  | 2,992 | ​ |  | 2,978 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Deferred tax liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation and amortization | ​ |  | (1,895) | ​ |  | (2,038) | ​
Operating lease assets | ​ |  | (2,002) | ​ | ​ | (1,985) | ​
Insurance related costs | ​ | ​ | (229) | ​ | ​ | (241) | ​
Inventory related costs | ​ | ​ | (283) | ​ | ​ | (259) | ​
Other | ​ | ​ | — | ​ | ​ | (16) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total deferred tax liabilities | ​ |  | (4,409) | ​ |  | (4,539) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net deferred tax liabilities | ​ | $ | (1,417) | ​ | $ | (1,561) | ​
​ As of February 3, 2024, deferred tax assets of $18 are included in “Other assets” in the Company’s Consolidated Balance Sheets. At February 1, 2025, the Company had net operating loss carryforwards for state income tax purposes of $1,283. The majority of these net operating loss carryforwards expire from 2025 through 2044. The utilization of certain of the Company’s state net operating loss carryforwards may be limited in a given year. Further, based on the analysis described below, the Company has recorded a valuation allowance against some of the deferred tax assets resulting from its state net operating losses. ​ At February 1, 2025, the Company had state credit carryforwards of $7 which expire from 2025 through 2038. The utilization of certain of the Company’s credits may be limited in a given year. Further, based on the analysis described below, the Company has recorded a valuation allowance against some of the deferred tax assets resulting from its state credits. ​ The Company regularly reviews all deferred tax assets on a tax filer and jurisdictional basis to estimate whether these assets are more likely than not to be realized based on all available evidence. This evidence includes historical taxable income, projected future taxable income, the expected timing of the reversal of existing temporary differences and the implementation of tax planning strategies. Projected future taxable income is based on expected results and assumptions as to the jurisdiction in which the income will be earned. The expected timing of the reversals of existing temporary differences is based on current tax law and the Company’s tax methods of accounting. Unless deferred tax assets are more likely than not to be realized, a valuation allowance is established to reduce the carrying value of the deferred tax asset until such time that realization becomes more likely than not. Increases and decreases in these valuation allowances are included in "Income tax expense" in the Consolidated Statements of Operations. As of February 1, 2025, February 3, 2024, and January 28, 2023, the total valuation allowance was $54, $55, and $83, respectively. ​ A reconciliation of the beginning and ending amount of unrecognized tax benefits, including positions affecting only the timing of tax benefits, is as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | 2024 |  | 2023 |  | 2022 |
Beginning balance | ​ | $ | 90 | ​ | $ | 93 | ​ | $ | 100 | ​
Additions based on tax positions related to the current year | ​ |  | 11 | ​ |  | 10 | ​ |  | 8 | ​
Additions for tax positions of prior years | ​ |  | 12 | ​ |  | 3 | ​ |  | 6 | ​
Reductions for tax positions of prior years | ​ |  | — | ​ |  | (9) | ​ |  | (4) | ​
Settlements | ​ | ​ | (4) | ​ |  | (1) | ​ |  | (9) | ​
Lapse of statute | ​ | ​ | (7) | ​ | ​ | (6) | ​ | ​ | (8) | ​
Ending balance | ​ | $ | 102 | ​ | $ | 90 | ​ | $ | 93 | ​
​ As of February 1, 2025, February 3, 2024, and January 28, 2023 the amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate was $70, $62, and $66, respectively. ​ To the extent interest and penalties would be assessed by taxing authorities on any underpayment of income tax, such amounts have been accrued and classified as a component of income tax expense. During the years ended February 1, 2025, February 3, 2024, and January 28, 2023, the Company recognized approximately $4, $1, and $(6), respectively, in interest and penalties (recoveries). The Company had accrued approximately $19, $15, and $14 for the payment of interest and penalties as of February 1, 2025, February 3, 2024, and January 28, 2023, respectively. ​ As of February 1, 2025, the years ended January 30, 2021 and forward remain open for review for federal income tax purposes.

X
- References No definition available. + Details
Name: | us-gaap_IncomeTaxDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for income tax. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContent Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details
Name: | us-gaap_IncomeTaxDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration